Macrocyclic Intermediate Synthesis via Phase Transfer Catalysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing synthesis processes for the HCV NS3/4A protease inhibitor TMC 435 face challenges in high yield and purity due to the formation of oligomeric byproducts during ring-closing metathesis, requiring tedious purification and harsh conditions for protective group removal, which complicates the production of this crucial anti-HCV drug.
Innovation Solution
A process involving the acylation of a diene compound with a halogenated acyl group followed by ring-closing metathesis using a suitable catalyst, allowing for easy removal of the halogenated acyl group in a one-pot procedure, thereby improving yield and purity without the need for additional purification steps or drastic deprotection conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If ring-closing metathesis is performed using Hoveyda-Grubbs first-generation catalyst in 1,2-dichloroethane at 75°C for 12 hours, then the macrocyclic compound is formed, but large amounts of oligomeric byproducts are formed and tedious purification procedures are required
Solution Approach 1:
A phase transfer catalyst (tetrabutylammonium fluoride or tetrabutylammonium hydroxide) is introduced as an intermediary substance to mediate the ring-closing metathesis reaction. This phase transfer catalyst enables the reaction to proceed in a biphasic system (organic solvent and aqueous base), which facilitates product formation while preventing oligomerization and simplifying purification through phase separation.
2Productivity
If N-protective group (Boc or benzoyl) is introduced to increase yield of ring-closing metathesis, then the yield is improved, but additional synthesis steps and purification are required and catalyst poisoning may occur
Solution Approach 1:
The invention removes the need for N-protective groups by extracting the problem of oligomerization and solving it through the phase transfer catalyst system. The secondary amide function remains unprotected while the phase transfer catalyst selectively promotes cyclization over oligomerization, eliminating the need for additional protection/deprotection steps.
3Ease of manufacture
If Boc-group is removed under drastic conditions (prolonged heating with strong acids), then the Boc-deprotection is achieved, but product decomposition occurs during the deprotection process
Solution Approach 1:
The invention extracts the need for drastic deprotection conditions by eliminating the Boc-protective group entirely. The phase transfer catalyst system enables the reaction to proceed without N-protection, and the mild basic aqueous workup selectively removes the phase transfer catalyst without requiring harsh acidic conditions that would decompose the product.
4Ease of manufacture
If benzoyl protective group is cleaved by treatment with bases such as KOH, then the cleavage is achieved, but product loss occurs due to non-selective attack of the base and ring opening of the macrocycle
Solution Approach 1:
The invention removes the need for base treatment to cleave protective groups by eliminating the benzoyl group entirely. The phase transfer catalyst approach allows the reaction to proceed with unprotected secondary amides, and the mild aqueous base workup used to remove the phase transfer catalyst does not cause macrocycle opening or significant product loss.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables a straightforward, efficient, and economic synthesis of the intermediate compound, facilitating the production of TMC 435 with high yield and purity, reducing the complexity of the synthesis and minimizing product loss.
Implementation Method 1
removing the halogenated acyl group from compound (III) thus obtaining the compound of formula (II)
Implementation Method 2
ring-closing metathesis of intermediate (44) in WO-2007/014926 is done by means of a Hoveyda-Grubbs first-generation catalyst
Data Source
Figure 1
AI summary
The present invention relates to an improved process for preparing (2R,3aR,10Z,11aS, 2aR,14aR)-cyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-12a(1H)-carboxylic acid, 2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-tetradecahydro-2-[[7-methoxy-8-methyl-2-[4-10 (1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5-methyl-4,14-dioxo-, ethyl ester. This compound is an intermediate in the overall synthesis route of the macrocyclic compound TMC 435. TMC 435 is an inhibitor of NS3/4A protease which plays an important role in the replication of the hepatitis C virus.